DSGN
Design Therapeutics Inc

381
Mkt Cap
$536.6M
Volume
101,683.00
52W High
$10.31
52W Low
$2.60
PE Ratio
-7.94
DSGN Fundamentals
Price
$9.33
Prev Close
$9.42
Open
$9.27
50D MA
$7.37
Beta
1.65
Avg. Volume
478,650.26
EPS (Annual)
-$0.8763
P/B
2.69
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Design Therapeutics (NASDAQ:DSGN) Stock Price Down 5.8% - Time to Sell?
Design Therapeutics (NASDAQ:DSGN) Stock Price Down 5.8% - Here's What Happened...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Design Therapeutics (NASDAQ:DSGN) Rating Lowered to "Sell" at Wall Street Zen
Wall Street Zen downgraded Design Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·6d ago
News Placeholder
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Rating of "Moderate Buy" by Brokerages
Shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the five ratings firms that are currently covering the firm...
MarketBeat·6d ago
News Placeholder
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Rating of "Moderate Buy" by Brokerages
Shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the five ratings firms that are currently covering the firm...
MarketBeat·6d ago
News Placeholder
Design Therapeutics (NASDAQ:DSGN) Sets New 1-Year High - Here's Why
Design Therapeutics (NASDAQ:DSGN) Reaches New 52-Week High - Time to Buy...
MarketBeat·7d ago
News Placeholder
Design Therapeutics (NASDAQ:DSGN) Trading Up 9% - What's Next?
Design Therapeutics (NASDAQ:DSGN) Trading 9% Higher - Here's What Happened...
MarketBeat·15d ago
News Placeholder
Design Therapeutics (NASDAQ:DSGN) Sets New 52-Week High - Still a Buy?
Design Therapeutics (NASDAQ:DSGN) Reaches New 52-Week High - Here's Why...
MarketBeat·16d ago
News Placeholder
Design Therapeutics (NASDAQ:DSGN) Given New $6.00 Price Target at Royal Bank Of Canada
Royal Bank Of Canada lifted their target price on shares of Design Therapeutics from $5.00 to $6.00 and gave the company a "sector perform" rating in a research note on Thursday...
MarketBeat·1mo ago
News Placeholder
Design Therapeutics (NASDAQ:DSGN) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS
Design Therapeutics (NASDAQ:DSGN - Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.30) earnings per share for the quarter, beating the consensus...
MarketBeat·1mo ago
News Placeholder
Biotech stocks jump as Makary outlines FDA vision, RBC comments
Investing.com -- Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers. In his first major interview since taking office, Makary emphasized pragmatic reforms, faster drug approvals, and modernized use of real-world data across the agency.
investing.com·8mo ago

Latest DSGN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.